دورية أكاديمية
أعرض في EDS

mTOR inhibitors for treatment of low-risk prostate cancer.

التفاصيل البيبلوغرافية
العنوان: mTOR inhibitors for treatment of low-risk prostate cancer.
المؤلفون: Liss MA; Department of Urology, University of Texas Health Science Center San Antonio, United States; Department of Nutritional Sciences, The University of Texas, Austin, United States; Department of Surgery, South Texas Veterans Healthcare System, San Antonio, TX, United States; UTHSA Cancer Center, San Antonio, TX, United States. Electronic address: liss@uthscsa.edu., Rickborn L; Department of Urology, University of Texas Health Science Center San Antonio, United States., DiGiovanni J; Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas, Austin, United States., Bacich D; Department of Urology, University of Texas Health Science Center San Antonio, United States., DeGraffenried LA; Department of Nutritional Sciences, The University of Texas, Austin, United States., Parihar M; Department of Molecular Medicine, University of Texas Health San Antonio, United States., Thompson IM; CHRISTUS Santa Rosa Medical Center, San Antonio, TX, United States., Sharp ZD; UTHSA Cancer Center, San Antonio, TX, United States; Department of Molecular Medicine, University of Texas Health San Antonio, United States; The Barshop Institute for Longevity and Aging Studies, United States.
المصدر: Medical hypotheses [Med Hypotheses] 2018 Aug; Vol. 117, pp. 63-68. Date of Electronic Publication: 2018 Jun 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Eden Press Country of Publication: United States NLM ID: 7505668 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2777 (Electronic) Linking ISSN: 03069877 NLM ISO Abbreviation: Med Hypotheses Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Elsevier, 2002- : Eden Press
Original Publication: Penrith, Eng., Eden Press.
مواضيع طبية MeSH: 5-alpha Reductase Inhibitors/*pharmacology , Prostatic Neoplasms/*drug therapy , TOR Serine-Threonine Kinases/*antagonists & inhibitors, Aged ; Animals ; Cell Line, Tumor ; Cellular Senescence ; Disease Progression ; Early Detection of Cancer ; Glucose Intolerance ; Humans ; Magnetic Resonance Imaging ; Male ; Mice ; Middle Aged ; Models, Theoretical ; Prostate/pathology ; Prostate-Specific Antigen/blood ; Proto-Oncogene Proteins c-akt/metabolism ; Receptors, Androgen/metabolism ; Sirolimus/pharmacology
مستخلص: Prostate cancer incidence increases with age; along with many other cancers, it could be considered a disease of aging. Prostate cancer screening has led to a significant proportion of men diagnosed with low-grade, low-stage prostate cancer who are now more likely to choose an active surveillance strategy rather than definitive treatments. Definitive treatment, such as surgery and radiation therapy, is useful for high-grade disease; however, because of the low long-term risk of progression of a low-grade disease and side effects of surgery and radiation, these treatments are less commonly used for low-grade disease. While five alpha reductase inhibitors have been shown to reduce the risk of cancer detection on subsequent biopsies for men on active surveillance, no medications have been proven to prevent progression to high-grade disease. mTOR pathways have long been known to influence prostate cancer and are targets in various prostate cancer patient populations. Low-dose mTOR inhibition with rapamycin has shown promise in pre-clinical models of prostate cancer and appear to affect cellular senescence and immunomodulation in the aging population. We hypothesize that low-dose mTOR inhibition could reduce progression of low-grade prostate cancer patients, allowing them to remain on active surveillance.
(Published by Elsevier Ltd.)
References: Diabetes. 2010 Jun;59(6):1338-48. (PMID: 20299475)
Aging Cell. 2016 Feb;15(1):28-38. (PMID: 26463117)
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):390-394. (PMID: 27431498)
Genes Dev. 2016 Jun 15;30(12):1383-8. (PMID: 27340174)
J Mol Med (Berl). 2011 Mar;89(3):221-8. (PMID: 21301797)
Cancer Cell. 2003 Sep;4(3):223-38. (PMID: 14522256)
Prostate Cancer Prostatic Dis. 2008;11(4):362-6. (PMID: 18283296)
Mol Immunol. 2008 May;45(10):2929-36. (PMID: 18343502)
Nat Rev Immunol. 2015 Oct;15(10):599-614. (PMID: 26403194)
Curr Opin Genet Dev. 2013 Feb;23(1):53-62. (PMID: 23317514)
Biochem J. 1995 Nov 15;312 ( Pt 1):163-7. (PMID: 7492307)
Nature. 2017 Jul 6;547(7661):109-113. (PMID: 28658205)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Genes (Basel). 2017 Feb 16;8(2):. (PMID: 28212321)
Clin Cancer Res. 2010 Jun 1;16(11):3057-66. (PMID: 20501622)
Cell Cycle. 2011 Dec 15;10(24):4217-24. (PMID: 22157190)
J Natl Cancer Inst. 2014 Feb;106(2):dju030. (PMID: 24511112)
Prostate. 2015 Jul 1;75(10):1020-33. (PMID: 25833062)
Anticancer Res. 2010 Oct;30(10):3895-901. (PMID: 21036700)
EMBO Rep. 2013 Mar 1;14(3):242-51. (PMID: 23399656)
Nature. 2009 Jul 16;460(7253):392-5. (PMID: 19587680)
Oncogene. 2008 Nov 27;27(56):7106-17. (PMID: 18776922)
J Gerontol A Biol Sci Med Sci. 2011 Feb;66(2):191-201. (PMID: 20974732)
Cancer Prev Res (Phila). 2015 Jul;8(7):597-606. (PMID: 25908508)
Transl Res. 2014 May;163(5):456-65. (PMID: 24316383)
Cancer Prev Res (Phila). 2014 Jan;7(1):169-78. (PMID: 24282255)
Aging Cell. 2014 Jun;13(3):468-77. (PMID: 24341993)
Age (Dordr). 2008 Dec;30(4):187-99. (PMID: 19424842)
Oncotarget. 2013 Dec;4(12):2451-61. (PMID: 24353195)
Cancer Res. 2006 Aug 1;66(15):7783-92. (PMID: 16885382)
Methods Mol Biol. 2012;821:295-303. (PMID: 22125073)
Curr Opin Cell Biol. 2015 Apr;33:55-66. (PMID: 25554914)
Am J Transplant. 2011 Mar;11(3):613-8. (PMID: 21342450)
Nat Rev Immunol. 2012 Apr 20;12(5):325-38. (PMID: 22517423)
J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):6-16. (PMID: 22451473)
Cancer Prev Res (Phila). 2011 Dec;4(12):2002-14. (PMID: 21952584)
Oncogene. 2016 Sep 8;35(36):4675-88. (PMID: 26829052)
Cancer Immunol Res. 2013 Dec;1(6):386-92. (PMID: 24778131)
Aging (Albany NY). 2014 Sep;6(9):742-54. (PMID: 25324470)
Transplantation. 2009 Apr 27;87(8 Suppl):S23-6. (PMID: 19384183)
Interdiscip Top Gerontol. 2013;38:1-16. (PMID: 23503511)
Mol Cell. 2010 Jul 30;39(2):171-83. (PMID: 20670887)
Cell Metab. 2016 Jun 14;23(6):990-1003. (PMID: 27304501)
Annu Rev Nutr. 2015;35:321-48. (PMID: 26185979)
Nature. 2006 Nov 16;444(7117):337-42. (PMID: 17086191)
Mol Cell Biol. 2011 Jul;31(14):2787-801. (PMID: 21576368)
PLoS One. 2011 Mar 04;6(3):e17449. (PMID: 21394210)
Curr Opin Cell Biol. 2011 Dec;23(6):744-55. (PMID: 21963299)
Target Oncol. 2011 Mar;6(1):41-51. (PMID: 21394528)
Science. 2013 Mar 15;339(6125):1323-8. (PMID: 23429703)
Oncogene. 2014 Jan 23;33(4):474-83. (PMID: 23318442)
J Immunol. 2010 Aug 15;185(4):2004-8. (PMID: 20631309)
Aging Cell. 2012 Aug;11(4):675-82. (PMID: 22587563)
Oncogene. 2006 Oct 16;25(48):6416-22. (PMID: 17041626)
Cell Metab. 2013 Nov 5;18(5):698-711. (PMID: 24206664)
JAMA. 2015 Jul 7;314(1):80-2. (PMID: 26151271)
Nat Immunol. 2013 Dec;14(12):1205-7. (PMID: 24240151)
Aging (Albany NY). 2013 Feb;5(2):100-10. (PMID: 23454836)
Lancet. 2012 Mar 24;379(9821):1103-11. (PMID: 22277570)
Sci Signal. 2015 Nov 10;8(402):ra113. (PMID: 26554817)
Oncotarget. 2015 Oct 13;6(31):31233-40. (PMID: 26378060)
Physiol Rev. 1997 Jul;77(3):731-58. (PMID: 9234964)
Biochim Biophys Acta. 2016 May;1862(5):992-1007. (PMID: 26639036)
Oncotarget. 2015;6(12):9718-27. (PMID: 25991667)
Mol Cell. 2006 Apr 21;22(2):159-68. (PMID: 16603397)
Clin Cancer Res. 2010 Jul 1;16(13):3322-8. (PMID: 20423984)
Science. 2016 Feb 12;351(6274):733-7. (PMID: 26912862)
Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R434-43. (PMID: 24965794)
Curr Biol. 2007 Jun 5;17(11):R415-7. (PMID: 17550767)
Cancer Res. 2011 Apr 15;71(8):2815-20. (PMID: 21487041)
J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):119-30. (PMID: 23682161)
Mech Ageing Dev. 2005 Sep;126(9):913-22. (PMID: 15885745)
Oncotarget. 2016 Jul 19;7(29):44876-44878. (PMID: 27384492)
Science. 2012 Mar 30;335(6076):1638-43. (PMID: 22461615)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
Cancer Prev Res (Phila). 2013 Jan;6(1):27-39. (PMID: 23248098)
Hum Pathol. 2015 Nov;46(11):1744-51. (PMID: 26344417)
Science. 2016 Feb 12;351(6274):728-733. (PMID: 26912861)
J Genet Genomics. 2014 Sep 20;41(9):459-63. (PMID: 25269671)
Sci Transl Med. 2014 Dec 24;6(268):268ra179. (PMID: 25540326)
Aging Cell. 2015 Dec;14(6):945-56. (PMID: 26315673)
Am J Physiol Endocrinol Metab. 2014 May 1;306(9):E1046-54. (PMID: 24619883)
Nat Immunol. 2013 Dec;14(12):1266-76. (PMID: 24141387)
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30. (PMID: 26733552)
Trends Immunol. 2009 May;30(5):218-26. (PMID: 19362054)
معلومات مُعتمدة: R01 CA193835 United States CA NCI NIH HHS
المشرفين على المادة: 0 (5-alpha Reductase Inhibitors)
0 (Receptors, Androgen)
EC 2.7.1.1 (MTOR protein, human)
EC 2.7.11.1 (AKT1 protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
EC 3.4.21.77 (Prostate-Specific Antigen)
W36ZG6FT64 (Sirolimus)
تواريخ الأحداث: Date Created: 20180806 Date Completed: 20181127 Latest Revision: 20211204
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6902872
DOI: 10.1016/j.mehy.2018.06.004
PMID: 30077200
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-2777
DOI:10.1016/j.mehy.2018.06.004